Zhengzhou Sino-American

Zhengzhou Sino-American Biological Technology is a Chinese biopharmaceutical company primarily focused on the research and development of innovative antiviral drugs. The company is most notable for its role in the early development and patenting of Azvudine (FNC), a nucleoside reverse transcriptase inhibitor. Azvudine has gained significant international attention as the first domestically developed oral antiviral approved in China for the treatment of COVID-19, having previously been approved for HIV-1. The company operates as a high-tech enterprise, leveraging collaborations with academic institutions like Zhengzhou University to translate basic research into clinical applications for infectious diseases.